Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending

This study analyzes partial orphan cancer drugs’ development, approval, and economics.

Source: Value in Health - January 18, 2024 Category: International Medicine & Public Health Authors: Thomas Michaeli, Daniel Tobias Michaeli Source Type: research